MDD Breakthrough EXXUA is a differentiated 5-HT1A agonist indicated for adults with major depressive disorder, offering psychiatrists a novel mechanism and a new treatment option to discuss with patients.

Go To Market Aytu collaborates with Fabre-Kramer Pharmaceuticals to commercialize EXXUA in the US, signaling a channel-savvy approach that can be expanded with co-promotion, specialty pharmacy distribution, and payer engagement.

Commercialization Leadership A Senior Vice President of Scientific Affairs strengthens medical affairs, education, and KOL engagement, enabling a targeted, physician-facing outreach plan to hospitals, clinics, and psychiatric practices.

Expansion Formulation The launch of EXXUA extended-release tablets indicates product line expansion that could broaden patient access; opportunities exist in patient support programs, payer optimization, and access strategies.

Market Momentum Active investor and conference presence suggests growing market interest; focus BD activities on health systems, managed care pilots, and specialty distributors to accelerate adoption.